ArticleBJC reports2026
Long-term outcomes and GVHD in allogeneic hematopoietic cell transplantation abroad: a 14-year UAE multi-center cohort.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic cell transplant (HCT) data are well reported, but for cohorts transplanted abroad and returning to countries without transplant services, long-term outcomes such as chronic graft versus host disease (GVHD) and overall survival remain poorly captured, underscoring the need for longitudinal follow-up.
methodsWe conducted a 14-year retrospective multi-center study of allogeneic HCT recipients followed at three tertiary hospitals in the United Arab Emirates(UAE). Transplant characteristics, conditioning, GVHD prophylaxis, and outcomes were abstracted from medical records. Crude survival was reported for all indications, Kaplan-Meier (KM) overall survival for diseases with ≥20 cases.
resultsA total of 363 allogeneic HCTs were analyzed. Overall, cohort characteristics differed from those reported in the literature: adults undergoing HCT were relatively young, female predominance was observed in pediatric malignancies and immune deficiencies, and matched unrelated donor (MUD) utilization was limited, while peripheral blood stem cell use was higher than typically described. In contrast, haploidentical donor utilization, conditioning intensity, and GVHD prophylaxis patterns were broadly consistent with international practice. GVHD incidence was high:69.2% in adults; 45.7% in children. In adults with acute myeloid leukemia (AML), acute GVHD was associated with an inferior 5-year OS (p = 0.036). In pediatric AML, both acute-/chronic GVHD were linked to poor survival (<50%), while survival for acute lymphoblastic leukemia (B-/T-ALL) exceeded 85%. cGVHD worsened overall survival (OS) more in pediatrics than adults.
conclusionsAlthough most findings aligned with established benchmarks, the high GVHD incidence and its association with adverse outcomes highlight the need for improved prevention strategies and the development of local transplant services.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.